In a report released on January 17, Cherilyn Radbourne from TD Cowen upgraded Canadian National Railway (CNI – Research Report) to a Buy, with ...

While she expects 2025 will likely be “another year of tepid growth” for North American railway companies, TD Cowen analyst Cherilyn Radbourne raised her rating for Canadian National Railway C ...

Investing.com -- LVMH is well-positioned for long-term success, despite some near-term challenges, according to analysts at TD Cowen. The bank maintains a positive outlook on the luxury giant ...

TD Cowen upgraded Salesforce's (NYSE:CRM) rating to Buy from Hold and raised the price target to $400 from $380. Shares of Salesforce rose about 2% on Friday. Analysts led by Derrick Wood said ...

STMicroelectronics (NYSE:STM) was in the spotlight on Monday as investment firm TD Cowen downgraded the industrial-focused semiconductor company, citing "broad-based semis cyclical headwinds." ...

On Tuesday, Forte Biosciences Inc. (NASDAQ:FBRX), a biotech company with a market capitalization of approximately $100 million, received a new Buy rating from TD Cowen, as the firm began its ...

Investing.com -- LVMH is well-positioned for long-term success, despite some near-term challenges, according to analysts at TD Cowen. The bank maintains a positive outlook on the luxury giant, ...

Fintel reports that on January 17, 2025, TD Cowen upgraded their outlook for Salesforce (WBAG:CRM) from Hold to Buy. There are 4,209 funds or institutions reporting positions in Salesforce.

TD Cowen assumed coverage on shares of Forte Biosciences (NASDAQ:FBRX – Free Report) in a report published on Tuesday morning, Marketbeat reports. The firm issued a buy rating on the stock.